fallopian tube neoplasms

Summary

Summary: Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.

Top Publications

  1. Kim J, Coffey D, Creighton C, Yu Z, Hawkins S, Matzuk M. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012;109:3921-6 pubmed publisher
    ..Thus, this mouse model demonstrates a paradigm for the origin and initiation of high-grade serous ovarian carcinomas, the most common and deadliest ovarian cancer...
  2. Shih K, Chi D, Barakat R, Leitao M. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol. 2010;117:330-5 pubmed publisher
    ..The objective of this study was to assess this potential survival benefit in a large cohort of patients with a long follow-up period...
  3. Shaw P, Rouzbahman M, Pizer E, Pintilie M, Begley H. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009;22:1133-8 pubmed publisher
    ..Tubal intraepithelial carcinoma, which, like invasive serous cancer, usually but not always overexpresses p53 protein, is more frequent in BRCA mutation carriers...
  4. Park J, Kim D, Suh D, Kim J, Kim Y, Kim Y, et al. Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol. 2008;15:2012-9 pubmed publisher
    ..To compare feasibility, accuracy, and safety of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer...
  5. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 2009;19:58-64 pubmed publisher
    ..Inflammatory markers could be detected in the vagina from the fallopian tube indicating possible chronic inflammation and a risk factor for mutagenesis leading to serous carcinoma. ..
  6. Aghajanian C, Blank S, Goff B, Judson P, Teneriello M, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039-45 pubmed publisher
  7. Pectasides D, Pectasides E, Papaxoinis G, Andreadis C, Papatsibas G, Fountzilas G, et al. Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol. 2009;115:97-101 pubmed publisher
    ..001). Optimally cytoreduced patients with PFTC treated with platinum and paclitaxel-based chemotherapy regimen have an excellent possibility of survival. ..
  8. Vang R, Shih I, Kurman R. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology. 2013;62:44-58 pubmed publisher
    ..This review paper provides an overview of the fallopian tube's potential role in the pathogenesis of both types of serous neoplasms of the ovary...
  9. Tone A, Begley H, Sharma M, Murphy J, Rosen B, Brown T, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res. 2008;14:4067-78 pubmed publisher

More Information

Publications69

  1. Carlson J, Miron A, Jarboe E, Parast M, Hirsch M, Lee Y, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160-5 pubmed publisher
    ..This study examined the frequency of STIC in PPSC and its clinical outcome in BRCA-positive women...
  2. Wethington S, Herzog T, Seshan V, Bansal N, Schiff P, Burke W, et al. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer. 2008;113:3298-306 pubmed publisher
    ..These malignancies are thought to behave biologically and clinically like ovarian cancer. The purpose of this study was to compare the clinical behavior and outcome of fallopian tube and ovarian cancer...
  3. Nezhat F, Ezzati M, Chuang L, Shamshirsaz A, Rahaman J, Gretz H. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. Am J Obstet Gynecol. 2009;200:83.e1-6 pubmed publisher
    ..To evaluate the role of laparoscopy for staging of early ovarian cancers...
  4. Maeda D, Takazawa Y, Ota S, Takeuchi Y, Seta A, Nakagawa S, et al. Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear. Int J Gynecol Pathol. 2010;29:273-7 pubmed publisher
    ..Clinicians and pathologists should consider the possibility of early tubal cancer when there is no clinically detectable pelvic mass, and malignant cells appear in endometrial cytology specimens...
  5. Perets R, Wyant G, Muto K, Bijron J, Poole B, Chin K, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013;24:751-65 pubmed publisher
    ..These findings offer an avenue to address clinically important questions that are critical for cancer prevention and early detection in women carrying BRCA1 and BRCA2 mutations. ..
  6. Nezhat F, DeNoble S, Liu C, Cho J, Brown D, Chuang L, et al. The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian, fallopian tube, and primary peritoneal cancers. JSLS. 2010;14:155-68 pubmed publisher
    ..To describe our experience with laparoscopic primary or interval tumor debulking in patients with presumed advanced ovarian, fallopian tube, or peritoneal cancers...
  7. Seidman J, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian ca. Gynecol Oncol. 2011;120:470-3 pubmed publisher
    ..This study was performed to evaluate this hypothesis in an unselected series of cases...
  8. Matulonis U, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27:5601-6 pubmed publisher
    ..Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit...
  9. Papadimitriou C, Markaki S, Lianos E, Peitsidis P, Vourli G, Nikitas N, et al. Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. Eur J Gynaecol Oncol. 2009;30:389-95 pubmed
    ..Primary fallopian tube carcinoma (PFTC) is a rare malignancy with only few data existing on the impact of prognostic factors...
  10. Roh M, Yassin Y, Miron A, Mehra K, Mehrad M, Monte N, et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol. 2010;23:1316-24 pubmed publisher
    ..PAX2 and PTEN, in addition to p53 and p16(ink4), comprise a potentially important gene combination in high-grade pelvic carcinogenesis...
  11. Mehrad M, Ning G, Chen E, Mehra K, CRUM C. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol. 2010;17:293-302 pubmed publisher
    ..Finally, the rationale for close inspection of the tube, both in presumed benign and malignant disease, is discussed, with reference to an ongoing multi-institutional web-based project (Pelvic-ovarian Cancer Interception project)...
  12. Bahar Shany K, Brand H, Sapoznik S, Jacob Hirsch J, Yung Y, Korach J, et al. Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma. Gynecol Oncol. 2014;132:322-7 pubmed publisher
    ..Our aim is to develop such an ex-vivo model based on human fallopian tube (FT) epithelium exposed to human follicular fluid (FF)...
  13. Kauff N, Satagopan J, Robson M, Scheuer L, Hensley M, Hudis C, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-15 pubmed
    ..We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations...
  14. Escobar P, Markman M, Rose P, Zanotti K, Webster K, Belinson J. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. 2004;92:192-6 pubmed
  15. Harries M, Moss C, Perren T, Gore M, Hall G, Everard M, et al. A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer. 2004;91:627-32 pubmed
    ..However, the observation of pulmonary toxicity, potentially a feature of the weekly taxane-gemcitabine regimen, was of some concern. Alternative schedules, including 3-weekly taxanes, are currently being evaluated...
  16. Finch A, Shaw P, Rosen B, Murphy J, Narod S, Colgan T. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64 pubmed
    ..To estimate the likelihood of occult cancer diagnosis at prophylactic oophorectomy in BRCA1 and BRCA2 carriers in different age groups and to determine the histopathology of these lesions...
  17. Haratz Rubinstein N, Fromberg E, Lederman S. Sonographic diagnosis of a serous tumor of low malignant potential of the fallopian tube. J Ultrasound Med. 2004;23:869-72 pubmed
  18. Saglam A, Bozdag G, Kuzey G, Kucukali T, Ayhan A. Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube. Arch Gynecol Obstet. 2008;277:557-62 pubmed
    ..To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube...
  19. Medeiros F, Muto M, Lee Y, Elvin J, Callahan M, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-6 pubmed
    ..Investigative strategies targeting the fimbriated end of the fallopian tube should further define its role in the pathogenesis of familial and sporadic ovarian serous carcinomas...
  20. Powell C, Kenley E, Chen L, Crawford B, McLennan J, Zaloudek C, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23:127-32 pubmed
    ..Two recent studies of BRCA mutation carriers reported occult malignancy in 2.5% of women undergoing RRSO. This study aimed to increase this detection rate using a protocol...
  21. Gaffan J, Herbertson R, Davis P, Dogan A, Jones A. Bilateral peripheral T-cell lymphoma of the fallopian tubes. Gynecol Oncol. 2004;95:736-8 pubmed
    ..Most cases of fallopian tube lymphoma reflect disease arising in the ovaries. All previously reported cases of primary lymphoma of the fallopian tube were of B cell lineage...
  22. Colgan T, Murphy J, Cole D, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25:1283-9 pubmed
    ..The entire ovaries and tubes from PO patients should be submitted for histologic examination to identify malignancy...
  23. Piek J, Kenemans P, Verheijen R. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol. 2004;191:718-32 pubmed
    ..In 3 hypotheses, 3 possible tissues of origin are proposed: the ovarian surface epithelium, the Fallopian tube epithelium, and the secondary Mullerian system...
  24. Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001;80:341-5 pubmed
    ..The goal of this work was to evaluate the importance of genetic factors in the etiology of fallopian tube cancer...
  25. Leblanc E, Querleu D, Narducci F, Occelli B, Papageorgiou T, Sonoda Y. Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol. 2004;94:624-9 pubmed
    ..A significant number of patients are referred to tertiary centers with inadequate staging information. We report on our experience with late results of laparoscopic restaging procedure in uncompletely managed early adnexal carcinomas...
  26. Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: a review. Oncologist. 2006;11:902-12 pubmed
    ..Primary fallopian tube carcinoma (PFTC) is a rare tumor that histologically and clinically resembles epithelial ovarian cancer (EOC). The purpose of this study is to review the current available literature data on PFTC...
  27. Levine D, Argenta P, Yee C, Marshall D, Olvera N, Bogomolniy F, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21:4222-7 pubmed
  28. Stewart S, Wike J, Foster S, Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol. 2007;107:392-7 pubmed
    ..The objective of this study was to report the incidence of primary fallopian tube carcinoma (PFTC) in the United States population and to describe associated demographic and clinical factors...
  29. Cass I, Holschneider C, Datta N, Barbuto D, Walts A, Karlan B. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet Gynecol. 2005;106:1327-34 pubmed
    ..To compare clinical and histologic features between fallopian tube cancers in women with germline BRCA mutations and sporadic cases...
  30. Crum C, Drapkin R, Miron A, Ince T, Muto M, Kindelberger D, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19:3-9 pubmed
  31. Søgaard M, Kjaer S, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand. 2006;85:93-105 pubmed
    ..If a woman does not want prophylactic oophorectomy, then tubal ligation or oral contraceptive use can be considered as these have been shown to reduce ovarian cancer risk also in mutation carriers...
  32. Gadducci A, Landoni F, Sartori E, Maggino T, Zola P, Gabriele A, et al. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol. 2001;81:150-9 pubmed
    ..The objective of this retrospective multicenter study was to assess the pattern of failures and survival of patients with primary carcinoma of the fallopian tube...
  33. Liapis A, Bakalianou K, Mpotsa E, Salakos N, Fotiou S, Kondi Paffiti A. Fallopian tube malignancies: A retrospective clinical pathological study of 17 cases. J Obstet Gynaecol. 2008;28:93-5 pubmed publisher
    ..The PFTC should be considered in the differential diagnosis of any pelvic mass. The treatment was surgical followed by adjuvant chemotherapy...
  34. Kindelberger D, Lee Y, Miron A, Hirsch M, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-9 pubmed
  35. Spirtos N, Eisekop S, Boike G, Schlaerth J, Cappellari J. Laparoscopic staging in patients with incompletely staged cancers of the uterus, ovary, fallopian tube, and primary peritoneum: a Gynecologic Oncology Group (GOG) study. Am J Obstet Gynecol. 2005;193:1645-9 pubmed
    ..The purpose of this study was to determine the feasibility of laparoscopically staging patients with incompletely staged cancers of the uterus, ovary, fallopian tube, and primary peritoneum, and to evaluate related effects...
  36. Chi D, Abu Rustum N, Sonoda Y, Ivy J, Rhee E, Moore K, et al. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005;192:1614-9 pubmed
    ..To compare the safety and efficacy of laparoscopic staging of ovarian or fallopian tube cancers to staging via laparotomy for epithelial ovarian carcinoma...
  37. Ayas S, Karateke A, Akoz I, Kir G, Yenidede I. Primary serous carcinoma of the fallopian tube with synchronous cervical epidermoid carcinoma in situ: a case report. Eur J Gynaecol Oncol. 2007;28:501-2 pubmed
    ..In conclusion, the genital tract should be examined in detail in case of any existence of a primary genital tumor and CA125 should be added to the examination...
  38. Callahan M, Crum C, Medeiros F, Kindelberger D, Elvin J, Garber J, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-90 pubmed
    ..To review the frequency and location of malignancies detected after prophylactic salpingo-oophorectomy in women with BRCA mutations...
  39. Riska A, Finne P, Koskela P, Alfthan H, Jalkanen J, Lehtinen M, et al. Human papillomavirus infection and primary fallopian tube carcinoma: a seroepidemiological study. BJOG. 2007;114:425-9 pubmed
    ..To evaluate the role of human papillomavirus (HPV) types 6, 11, 16, 18, 31 or 33 infection in primary fallopian tube carcinoma (PFTC)...
  40. Lee Y, Miron A, Drapkin R, Nucci M, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35 pubmed
  41. Benoit M, Hannigan E. A 10-year review of primary fallopian tube cancer at a community hospital: a high association of synchronous and metachronous cancers. Int J Gynecol Cancer. 2006;16:29-35 pubmed
    ..The median follow-up was 38 months. This report details the diagnostic and therapeutic experience of patients with PFTC and describes the occurrence of synchronous and metachronous gynecological cancers...
  42. Noack F, Lange K, Lehmann V, Caselitz J, Merz H. Primary extranodal marginal zone B-cell lymphoma of the fallopian tube. Gynecol Oncol. 2002;86:384-6 pubmed
    ..Only 2% of all extranodal primary lymphomas affect the female genital tract. Involvement of the fallopian tubes by primary lymphoma is extremely rare...
  43. Crum C, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5:35-44 pubmed
  44. Chi D, Franklin C, Levine D, Akselrod F, Sabbatini P, Jarnagin W, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650-4 pubmed
  45. Agoff S, Mendelin J, Grieco V, Garcia R. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol. 2002;26:171-8 pubmed
  46. Chi D, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao M, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124:10-4 pubmed publisher
    ..PDS should continue to be the preferred initial management for patients with bulky stages IIIC-IV ovarian carcinoma. NACT should be reserved for those who cannot tolerate PDS and/or for whom optimal cytoreduction is not feasible. ..
  47. Bruchim I, Weeg N, Alpert Y, Sade D, Piura E, Fishman A. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study. Int J Gynecol Cancer. 2016;26:640-7 pubmed publisher
    ..Future larger studies should focus on strategies to compare this regimen to the current standard, with an emphasis on quality of life. ..
  48. Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn L. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol. 2011;30:417-24 pubmed publisher
    ..Immunohistochemistry for p53 and ki-67 may aid in the diagnosis, but is not necessary for routine investigation. ..
  49. Chumworathayi B. Personalized cancer treatment for ovarian cancer. Asian Pac J Cancer Prev. 2013;14:1661-4 pubmed
    ..Among the advanced refractory ovarian cancers cases (N=33), an objective response (OR) was found in 42.4%. We anticipate that with improved technology and novel therapeutics this rate will increase and adverse events will be reduced. ..
  50. Meserve E, Mirkovic J, Conner J, Yang E, Muto M, Horowitz N, et al. Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. Gynecol Oncol. 2017;146:69-73 pubmed publisher
    ..However, the significance of lesser tubal atypias (0.3% in this study), risk of STIC in women with no epithelial pathology and the risk imposed by coexisting endometrioid neoplasia are unclear and require further study. ..
  51. Nelson H, Pappas M, Zakher B, Mitchell J, Okinaka Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014;160:255-66 pubmed
    ..Studies of risk assessment, genetic counseling, genetic testing, and interventions to reduce cancer and mortality indicate potential benefits and harms that vary according to risk. ..
  52. Shaaban A, Rezvani M. Imaging of primary fallopian tube carcinoma. Abdom Imaging. 2013;38:608-18 pubmed publisher
    ..This article discusses the history, pathology, and patterns of spread of fallopian tube carcinoma, as well as reviewing and illustrating the cross-sectional imaging findings. ..
  53. Peitsidis P, Peitsidou A, Papadimitriou C, Rodolakis A, Tsekoura V, Akrivos T. Correlation of dermatomyositis with fallopian tube carcinoma: A potential paraneoplastic syndrome. J Obstet Gynaecol. 2008;28:365-6 pubmed publisher
  54. Anderson C, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman M. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013;23:417-21 pubmed publisher
    ..This article reviews the possibility of applying risk-reducing salpingectomy as a new paradigm for the prevention of pelvic serous cancer in both high- and low-risk women. ..
  55. Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, et al. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Gynecol Oncol. 2010;118:155-9 pubmed publisher
    ..The purpose of this study was to identify risk factors for fallopian tube cancer in women with and without a BRCA mutation...
  56. Yokoyama Y, Futagami M, Fujimoto T, Terada Y, Takatori E, Sugiyama T, et al. Investigation of the clinicopathological features of fallopian tube malignancy. Oncol Rep. 2013;30:79-84 pubmed publisher
    ..These results suggest that since FTM frequently results in solitary recurrence, aggressive recurrence treatment including SDS could improve prognosis...
  57. Martin L, Sill M, Shahin M, Powell M, Disilvestro P, Landrum L, et al. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2014;132:526-30 pubmed publisher
  58. Uehara T, Onda T, Togami S, Amano T, Tanikawa M, Sawada M, et al. Safety and efficacy of a splenectomy during debulking surgery for Müllerian carcinoma. Eur J Gynaecol Oncol. 2011;32:269-73 pubmed
    ..This study was designed to assess the safety and efficacy of a splenectomy and to analyze the prognostic factors of Müllerian carcinoma with spleen metastasis...
  59. Ma C, Yang S, Huang C, Chai C, Cheng K, Tsai E, et al. Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review. Eur J Gynaecol Oncol. 2008;29:289-93 pubmed
    ..The prognosis of MMMT is catastrophic and the treatment is based on the experience of those of uterine sarcomas, which is composed of operation, radiotherapy and chemotherapy...
  60. Otsuka I, Matsuura T. Skin metastases in epithelial ovarian and fallopian tube carcinoma. Medicine (Baltimore). 2017;96:e7798 pubmed publisher
    ..Nonumbilical metastases occurring in incisional scars of primary surgery may carry a favorable prognosis...